1. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
- Author
-
Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo, Lorenzo Iovino, Ana Alarcon Tomas, Craig Sauter, Miguel-Angel Perales, Nirav. N. Shah, Utkarsh H. Acharya, Caron Jacobson, Robert J. Soiffer, Trent Wang, Krishna V. Komanduri, Samantha Jaglowski, Adam S. Kittai, Nathan Denlinger, Madiha Iqbal, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Julio Chavez, Michael Jain, Frederick L. Locke, Yazeed Samara, Lihua E. Budde, Matthew G. Mei, Alexandra Della Pia, Tatyana Feldman, Nausheen Ahmed, Ryan Jacobs, Nilanjan Ghosh, Bhagirathbhai Dholaria, Olalekan O. Oluwole, Brian Hess, Ayesha Hassan, Vaishalee P. Kenkre, Patrick Reagan, Farrukh Awan, Yago Nieto, Mehdi Hamadani, and Alex F. Herrera
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR T failure. Eighty-eight patients with relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR T failure. The median number of lines of therapy between CAR T infusion and alloHCT was one (range, 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral blood was the most common graft source (86%, n=76). The most common donor types were matched unrelated donor (39%), followed by haploidentical (30%) and matched related donor (26%). Median follow-up of survivors was 15 months (range, 1-72). One-year overall survival, progression-free survival, and graft-versus-host disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analysis,
- Published
- 2022
- Full Text
- View/download PDF